F. Hamy

发表

Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles.

John A. Robinson, T. Klimkait, S. DeMarco, 2006, Bioorganic & medicinal chemistry.

Cooperativity in the binding of echinomycin to DNA fragments containing closely spaced CpG sites.

M. Waring, C. Bailly, F. Hamy, 1996, Biochemistry.

The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.

E. Rubin, C. Bailly, H. Vezin, 1999, Biochemistry.

The chromosomal protein HMG‐D binds to the TAR and RBE RNA of HIV‐1

C. Bailly, A. Travers, P. Arimondo, 2000, FEBS letters.

Molecular basis of HIV-1 TAR RNA specific recognition by an acridine tat-antagonist.

C. Bailly, F. Hamy, N. Gelus, 1999, Bioorganic & medicinal chemistry.

The HIV Tat-TAR interaction, a novel target for drug discovery

J. Karn, G. Varani, E. Felder, 1998 .

The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism.

C. Bailly, P. Colson, C. Houssier, 1996, Nucleic acids research.

Specific block of androgen receptor activity by antisense oligonucleotides

T. Klimkait, V. Brondani, F. Hamy, 2003, Prostate Cancer and Prostatic Diseases.

Rational optimization of a HIV-1 Tat inhibitor: rapid progress on combinatorial lead structures.

E. Felder, T. Klimkait, F. Hamy, 1998, Biotechnology and bioengineering.

Thiated derivatives of 2',3'-dideoxy-3'-fluorothymidine: synthesis, in vitro anti-HIV-1 activity and interaction with recombinant drug resistant HIV-1 reverse transcriptase forms.

T. Klimkait, M. Figlerowicz, A. Kurzyńska-Kokorniak, 2011, Antiviral research.

The peptidyl-prolyl isomerase Pin1 regulates phospho-Ser77 retinoic acid receptor alpha stability.

T. Klimkait, V. Brondani, F. Hamy, 2005, Biochemical and biophysical research communications.

Blocking HIV replication by targeting Tat protein.

T. Klimkait, C. Bailly, M. Zeller, 2000, Chemistry & biology.

A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition.

T. Klimkait, M. Blommers, A. Flörsheimer, 1998, Biochemistry.

High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region.

J. Karn, P. Butler, C. Dingwall, 1993, Journal of molecular biology.

Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure.

C. Bailly, P. Colson, C. Houssier, 1997, Nucleic acids research.

Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.

T. Klimkait, S. Louvel, O. Potterat, 2012, Journal of natural products.

Detection of drug‐resistant HIV minorities in clinical specimens and therapy failure

M. Battegay, P. Vernazza, T. Klimkait, 2008, HIV medicine.

A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.

E. De Clercq, C. Pannecouque, T. Klimkait, 2000, Molecular pharmacology.

TAR-RNA binding by HIV-1 Tat protein is selectively inhibited by its L-enantiomer.

T. Klimkait, A. Garbesi, F. Hamy, 1998, Nucleic acids research.

Promoter of FGF8 reveals a unique regulation by unliganded RARalpha.

T. Klimkait, J. Egly, V. Brondani, 2002, Journal of molecular biology.

An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication.

J. Karn, G. Varani, E. Felder, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins

Michael J. Gait, Mohinder Singh, Clare E. Pritchard, 1994, Nucleic Acids Res..

Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.

M. Suchard, K. Anastos, T. Klimkait, 2012, AIDS research and human retroviruses.

Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care

M. Battegay, T. Klimkait, H. Hirsch, 2005, European Journal of Clinical Microbiology and Infectious Diseases.

Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.

T. Klimkait, V. Soriano, Á. Holguín, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Hydrogen-bonding contacts in the major groove are required for human immunodeficiency virus type-1 tat protein recognition of TAR RNA.

J Grasby, J. Karn, J. Grasby, 1993, Journal of molecular biology.

An ARE-selective DNA minor groove binder from a combinatorial approach.

C. Bailly, A. Flörsheimer, F. Hamy, 2000, Biochemical and biophysical research communications.

The peptidyl–prolyl isomerase Pin1 regulates phospho-Ser77 retinoic acid receptor α stability

T. Klimkait, V. Brondani, F. Hamy, 2005 .

Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study

H. Günthard, M. Battegay, P. Vernazza, 2011, Journal of Translational Medicine.

Localized chemical reactivity in DNA associated with the sequence-specific bisintercalation of echinomycin.

M. Waring, C. Bailly, D. Gentle, 1994, The Biochemical journal.

Nuclear targeting of a viral-cointernalized protein by a short signal sequence from human retinoic acid receptors.

P. Verwaerde, J. Hénichart, F. Hamy, 1991, Bioconjugate chemistry.

Inhibition of HIV-1 Tat-TAR interaction by diphenylfuran derivatives: effects of the terminal basic side chains.

T. Klimkait, C. Bailly, W. Wilson, 1999, Bioorganic & medicinal chemistry.

Susceptibility of Diverse HIV-1 Patient Isolates to the Maturation Inhibitor, Bevirimat (MPC-4326*), is Determined by Clade- Specific Polymorphisms in Gag CA-SP1

David E. Martin, François Hamy, T. Klimkait, 2009 .

Retinoic acid switches differential expression of FGF8 isoforms in LNCaP cells.

V. Brondani, F. Hamy, 2000, Biochemical and biophysical research communications.

Discovery of Highly Potent and Selective CXCR4 Inhibitors Using Protein Epitope Mimetics (PEM) Technology

John A. Robinson, T. Klimkait, S. DeMarco, 2007 .